Fierce Biotech

Merck's HIV combo matches Gilead's Biktarvy in latest phase 3 test for islatravir

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Merck HIV therapy matches Gilead’s Biktarvy in late-stage trial

Merck (MRK) stock gains as new oral HIV tablet matches Gilead's (GILD) three-drug once-daily HIV pill Biktarvy in a Phase 3 ...

Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.
Seeking Alpha

Gilead Sciences Q2: The New Drug That Could Change Everything

Gilead Sciences, Inc.’s HIV franchise, led by Biktarvy, ensures stable cash flows through 2033, providing long-term visibility and a strong competitive advantage. The launch of Yeztugo, a biannual ...